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ABSTRACT
Proteins such as albumin, gelatin, casein, transferrin, and collagen are widely used as drug delivery sys-
tems. However, only albumin-based paclitaxel (PTX) formulation AbraxaneVR (PTX-albumin NPs prepared
by nab-technology) has been successfully developed for treating metastatic breast cancer clinically
due to abundant materials, simple industrial scale-up process, and well tumor-targeting ability.
Hemoglobin (Hb) is another protein used for drug delivery with similar advantages. In this study, we
successfully synthesized PEG-Hb nanoparticles loading with PTX based on previously well-established
acid-denatured method. PEG-Hb-PTX NPs showed enhanced cellular uptake and great cellular inhib-
ition ability in vitro. Moreover, our animal study showed that PEGylated NPs greatly accumulated in
tumor tissues and exhibited excellent anticancer activity in vivo. We found that PEG-Hb-PTX NPs pos-
sess a better in vivo antitumor effect than the commercially available TaxolVR formulation. We believe
that PEG-Hb has great potential as an efficient drug delivery system for further clinic study.
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Antitumor drugs are often highly effective at destroying
tumor cells but with concomitant side effects and poor tar-
get specificity (Cho et al., 2008). Besides, some anticancer
drugs, such as paclitaxel (PTX), camptothecin (CPT), and cur-
cumin (CCM), have poor solubility problem because of their
hydrophobic nature (Yap et al., 2010). To overcome these
problems, advanced drug delivery systems (DDS) are highly
needed (Wang et al., 2014; Zhang et al., 2015; Zhu et al.,
2015; Wang et al., 2016; Zhao et al., 2019). Among them,
protein-based drug carriers have great potential in drug
delivery area due to biodegradability, non-immunogenicity,
and biocompatibility compared to synthetic polymers (Gong
et al., 2011). Many proteins including gelatin, casein, albumin,
and collagen have been used as DDS (Lai & Guo, 2011; Papi
et al., 2011; Meng et al., 2015). Albumin is an attractive pro-
tein carrier and widely used as drug carrier. For example,
albumin-based PTX formulation AbraxaneVR (PTX-albumin NPs
prepared by nab-technology) has been successfully devel-
oped for treating metastatic breast cancer clinically
(Altundag et al., 2006; Elzoghby et al., 2012). Abundant mate-
rials, simple industrial scale-up process, and well tumor-tar-
geting ability are the main features for the successful clinical
application of PTX-albumin NPs (AbraxaneVR ). Recently,
researchers have found that protein hemoglobin (Hb) can
also be used as drug carrier. Hb is roughly spherical, with a
diameter of nearly 5.5 nm and molecular weight of 64.5 kDa
(Ingram et al., 1962). It is a tetrametric protein consisting of
two pairs of a and b subunits, and each subunit contains a
heme group in its hydrophobic region (Perutz, 1978). Hb is a
traffic protein carrying oxygen and carbon dioxide in vivo
(Lalezari et al., 1990). In addition, Hb has a high affinity for
CD163 after binding with haptoglobin (Meng et al., 2015). All
of these advantages make hemoglobin an excellent drug car-
rier, and several studies have attempted to conjugate drugs
with Hb via chemical bonds (Brookes et al., 2006). However,
complex synthesis steps caused low drug-loading efficiency.
For example, Brookes et al. had developed hemoglobin-riba-
virin conjugates for targeting therapy purpose, while only six
to eight ribavirin moieties attached per hemoglobin (Brookes
et al., 2006; Zhang & Palmer, 2011).
Our group had developed a novel acid denatured method
by using Hb as drug carrier to synthesize drug-loaded nano-
particles by non-covalent forces (mainly hydrophobic inter-
action). However, Hb nanoparticles are not stable in
physiological environment (pH 7.4), resulting in bad perform-
ance in vivo especially via intravenous injection. Coating the
surface of materials with polyethylene glycol (PEG), or
“PEGylation,” is a common approach for improving the effi-
ciency of drug delivery in vivo (Veronese & Mero, 2008). In
this study, we modified Hb with PEG to improve the
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nanoparticle stability both in vitro and in vivo. The PEGylated
Hb (PEG-Hb) formed nanoparticles loaded with hydrophobic
PTX by acid-denatured method. Near-infrared fluorescence
imaging showed that PTX-loaded PEG-Hb nanoparticles (PEG-
Hb-PTX NPs) had great tumor accumulation ability. We found
that PEG-Hb-PTX NPs possess a better in vivo antitumor
effect than the commercially available TaxolVR formulation.
2. Materials and methods
2.1. Materials
Human Hb (99%) was obtained from Sigma-Aldrich (MO,
USA). Carboxylate-functionalized PEG (COOH-PEG, MW 2000)
was obtained from Sigma-Aldrich (MO, USA). PTX was
obtained from Hongdoushan Co. Ltd. (Jiangsu, China).
TaxolTM was obtained from Jiangsu Province Hospital
(Nanjing, China). Human breast cancer cell line (MCF-7) was
obtained from Shanghai Institute of Cell Biology (Shanghai,
China). IR775 iodide was purchased from Sigma-Aldrich
(St Louis, MO, USA). Trypsin, penicillin, streptomycin, fetal
bovine serum (FBS), and RPMI-1640 medium were obtained
from Hyclone (Waltham, USA). All other reagents were from
Nanjing Wanqing Chemical Glassware Instrument (Nanjing,
China).
2.2. PEGylation and characterization of Hb
The COOH-PEG and Hb solution were mixed and stirred over
night with ice bath in the presence of excess N-hydroxysucci-
nimide (NHS) and 1-ethyl-3-(3-dimethylaminopropyl)-carbo-
diimide (EDC). The resulting PEG-Hb was isolated by dialyzed
in deionized water.
The PEG-Hb was identified by SDS-PAGE analysis (Sun &
Palmer, 2008). Hb and PEG-Hb samples were loaded into a
4% stacking gel with a 12% resolving gel and subjected to
electrophoresis at 100 V for about 1 h. After that, the gels
were stained for 30min using Coomassie blue dye R250 and
washed overnight with bleaching dye (25% ethanol and 8%
acetic acid). Finally, the gel was visualized using Tanon 5200
multi-imaging system (Tanon Science & Technology Inc.,
Shanghai, China).
2.3. Preparation of PTX-loaded PEG-Hb nanoparticles
(PEG-Hb-PTX NPs)
PEG-Hb-PTX NPs were prepared via an acid-denaturing
method as described previously (Wang, Wang, et al., 2015;
Wang, Chen, et al., 2017). Beriefly, 10mL PEG-Hb (2mg/mL)
solution in distilled water was stirred at a speed of 600 rpm.
Then, the pH value of Hb solution was adjusted to 4.0 by
2M HCl. After 10-min stirring, 2mg PTX (10mg/mL, dissolved
in ethanol) was added into the protein solution drop by
drop to form nanoparticles. Then, the nanoparticle solution
was ultrafiltrated (membrane cutoff MW 30 KDa, Millipore) to
remove ethanol and unbound PTX. As a control, PTX-loaded
Hb nanoparticles (Hb-PTX NPs) were prepared as the same
method above. The amount of PTX in both NPs was tested
by HPLC. Acetonitrile/water (55/45, v/v) was used as the
mobile phase at a flow rate of 1.0mL per minute.
2.4. Characterization of PEG-Hb-PTX NPs
Particle size was determined by Zeta Plus (Brookhaven, USA).
The NPs were also observed under a transmission electron
microscope (TEM, EM-200CX, JEOL, Japan). For the stability
assay, PEG-Hb-PTX NPs and Hb-PTX NPs were diluted in PBS,
respectively. The stability of PEG-Hb-PTX NPs was also tested
in fetal blood serum (37 C). The mean diameter changes of
NPs were monitored at time intervals. The release of PTX
was performed according to the dialysis method. Briefly, the
NPs were put into a dialysis bag (MWCO 3500). Then, the
bag was immerged into release medium that consisted of
15mL of 0.1M PBS (pH 7.4 and 5.5) and 1% Tween 80 (v/v),
and kept at 37 C. At specified time points, the release
medium was withdrawn for HPLC analysis, and equivalent
release medium was added.
To study the forming mechanism of PEG-Hb NPs, the
exposure of tryptophan residues was detected by monitoring
the fluorescence intensity of tryptophan in PEG-Hb using an
RF-5301PC fluorescence spectrophotometer (Shimadzu,
Japan) at 0.5-nm intervals. Tryptophan emits fluorescence at
300 to 380 nm, under excitation at 280 nm. The hydrophobic
dye ANS was used as an indicator of exposure of hydropho-
bic clusters for its high affinity to PEG-Hb. 40 lM ANS was
added to PEG-Hb at pH 4.0, 6.0 and 6.6, respectively. The
fluorescence at 400 to 600 nm was recorded after 15min
(when the value was stable) at 0.5-nm intervals, with 380 nm
as the excitation wavelength.
2.5. Cytotoxicity
MCF-7 cells (5 103 per well) were seeded into 96-well
plates. After incubation for 24 h, the cells were treated with a
series of increasing concentrations (0.0001, 0.001, 0.01, 0.1, 1,
and 10 lg/mL of PTX) for 24 h. Then, CCK-8 (10lL) was
added to each well in the 96-well plate and incubated for an
additional 2 h at 37 C in a humidified incubator with 5%
CO2. Finally, the absorbance was measured at a wavelength
of 450 nm. Cell viability was normalized to untreated cells
and expressed as the mean± SD of triplicate samples.
2.6. Cellular uptake in vitro
Coumarin-6 (cou6) is a good fluorescence dye for cell uptake
study. Here, cou6 was mixed with PTX (1:100¼ cou6: PTX,
wt/wt) to prepare cou6 contained PEG-Hb-PTX NPs or Hb-
PTX NPs. Briefly, MCF-7 cells (1.0 104 per well) were seeded
in confocal dishes overnight and cultured for 24 h at 37 C in
a humidified incubator with 5% CO2. Then, the medium was
changed to the fresh medium containing free cou6, Hb-PTX
NPs and Hb-PTX NPs contained the same concentration of
PTX (0.0045mg/mL) and cou6. After 2-h incubation, the cells
were washed two times with PBS and fixed with 4% parafor-
maldehyde solution for 30min, and then stained with DAPI
for 15min. Finally, the cells were observed by confocal
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microscopy with kex/em 346/460 nm for DAPI and kex/em
488/500-550 nm for cou6.
2.7. Imaging, biodistribution, and pharmacokinetic
studies in vivo
All animal experiments were conducted in compliance with
the Institutional Animal Care and Use Committee of Nanjing
University. Pathogen-free 6-week-old male ICR mice were
acclimatized for 1week before establishing tumor model.
Then, H22 tumor cells (5.0 106 cells per mouse) were inocu-
lated subcutaneously to ICR mice at the right axilla. To visu-
alize the distribution of PEG-Hb-PTX NPs in vivo, IR-775 NIR
dye and PTX (1:10, wt/wt) were simultaneously co-encapsu-
lated into NPs via this same method as described in Section
2.3. Then, the NPs with or without PEG (0.3mg/kg IR775) and
free IR-775 (0.3mg/kg) were intravenously injected to H22
tumor-bearing mice via tail vein. Mice were anesthetized and
observed under the IVIS Lumina system (Xenogen Co.,
Alameda, CA) at 0.5, 1, 3, 18, 24, 48, and 72 h after adminis-
tration. The excitation wavelength was 745 nm and the
exposure time was 2 s. IVIS Living Imaging Software was
used for the analysis of the amount of IR775 in tissues.
For the pharmacokinetic study, the ICR mice were divided
in two groups (three mice for each time points). The first
group received intravenously by the vein of the tail 10mg/
kg of PTX as Taxol. The other group received PEG-Hb-PTX
NPs (PTX, 10mg/kg). Blood samples were collected at
0.25–8 h (0.25, 0.5, 1.0, 1.5, 2.0, 3.0, 4.0 and 8.0 h) after
administration, and serum was obtained after centrifugation
for 10min at 10,000 rpm. The concentration of PTX in the
serum samples was determined using a standard curve of
PTX and measured using HPLC. The pharmacokinetic param-
eters were calculated by PK Solver Version 2.0 (Zhang
et al., 2010).
2.8. Antitumor activity in vivo
H22 tumor cells (5.0 106) were engrafted subcutaneously to
the right axilla of ICR mice (6weeks old). When the tumor
volume reached 100mm3 (designated as day 0), mice were
randomly divided into three groups (n¼ 6). On day 1, free
PTX (Taxol, 10mg/Kg) and PEG-Hb NPs (10mg/Kg) were
intravenously administered, respectively, while PBS was used
as normal control. Treatments were performed twice, on day
1 and day 3. Tumor volume was measured using digital cali-
pers. The volume was calculated as the following formula:
tumor volume (mm3)¼ 0.5 lengthwidth2. Body weight of
the mice was also recorded.
2.9. Statistics
Statistical assessment was conducted by two-sided Student’s
t test for two groups and one-way analysis of variance for
multiple groups (p< 0.05 was considered statistically
significant).
3. Results and discussion
3.1. Preparation and characterization of PEG-Hb-
PTX NPs
The synthesized PEGylated Hb was detected by SDS-PAGE
(Figure S1). We then used one-step acid-denaturing method
to encapsulate PTX in Hb NPs (Figure 1(A)). This method
takes advantage of the exposure of hydrophobic domains of
PEG-Hb under acidic conditions to facilitate hydrophobic
interactions with PTX. The TEM image revealed that PEG-Hb-
PTX NPs appeared as spherical nanoparticles and showed a
homogeneous structure (Figure 1(B)). Hydrodynamic size of
the PEG-Hb-PTX NPs was measured by DLS, which was in a
narrow distribution and ranged around 180 190 nm (Figure
1(C)). The prepared nanoparticles with this size range cannot
Figure 1. Assemble and characterization of PEG-Hb-PTX NPs. (A) Preparation of PEG-Hb-PTX NPs using one-step acid-denaturing method. (B) TEM of PEG-Hb-PTX
NPs. (C) Size distribution of PEG-Hb-PTX NPs determined by DLS. (D) Changes in particle size of PEG-Hb-PTX NPs at different time points in PBS.
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be easily phagocytized in the blood circulation compared to
larger nanoparticles. PEG-Hb-PTX NPs were determined for
the cumulative release of encapsulated PTX under different
pH value condition (Figure S2). The drug release data
showed that PTX encapsulated within PEG-Hb-PTX NPs was
released statistically significantly higher at pH 5.5 than pH 7.
4. PEGylation was expected to stabilize the NPs in their
in vivo application. The stability of the Hb-PTX NPs and PEG-
Hb-PTX NPs was investigated by DLS in PBS and fetal blood
serum. As demonstrated in Figure 1(D) and Figure S3, the
hydrodynamic size of Hb-PTX NPs increased quickly in PBS,
which resulted from the aggregation of the NPs. In contrast,
the PEG-Hb-PTX NPs had stable particle size during the
tested period (Figure 1(D)).
3.2. Mechanism of PEG-Hb NPs formation
Our previous study showed that hydrophobic interactions
play a significant role in the preparation of acid-denaturing
Hb NPs (Wang et al., 2015). Hb has a large number of hidden
Tryptophan (Trp) residues which are limited to hydrophobic
areas in a close proximity to the heme group (Kristinsson,
2002). Trp fluorescence indicates that the exposure of hydro-
phobic areas is inside of the protein. Under normal physio-
logical conditions, quenching of these residues could take
place from surrounding groups and resulting in a limited
exposure to the solvent. Here, we test the Trp fluorescence
change in PEGylated Hb. As shown in Figure 2(A), while
decreasing the pH from 6.6 to 4.0, the fluorescence of Trp
was dramatically increased. Because the exposure of hidden
Trp residues as the protein is unfolded, the hydrophobic
domain inside of the protein is exposed under lower pH. To
further confirm the exposure of hydrophobic residues in
PEG-Hb, ANS binding assay was used (Gong et al., 2012). The
ability of the hydrophobic residues binding the hydrophobic
dye ANS was increased at low pH value (pH 4.0), whereas
the binding ability decreased when the pH values increased,
indicating from the ANS fluorescence intensity in Figure 2(B).
Therefore, hydrophobic force may mainly facilitate the forma-
tion of PEG-Hb NPs.
3.3. Cytotoxicity and cellular uptake of PEG-Hb-PTX NPs
To investigate the cytotoxicity of the NPs with or without
PEGylation, the cytotoxicity of the PEG-Hb-PTX NPs was con-
ducted using MCF-7 cells. MCF-7 cells were incubated with
TaxolTM, Hb-PTX NPs, and PEG-Hb-PTX NPs at different con-
centrations (0.0001, 0.001, 0.01, 0.1, 1, and 10 lg/mL) for
24 h. As shown in Figure 3(A), the cell viability of PEG-Hb-
PTX NPs was lower than that of Hb-PTX NPs at all detected
concentrations. Only when the concentrations of PTX up to
0.1 lg/mL, TaxolTM treatment led to more cell death than
PEG-Hb-PTX NPs. This may be due to organic solvent in
TaxolTM, while our PEG-Hb-PTX NPs was organic solvent free
(Wu et al., 2013).
To further investigate the details of improving cell killing
of PEG-Hb-PTX NPs, we compared the cellular uptake of the
PEGylated and non-PEGylated NPs. Cou6, a hydrophobic dye,
was simultaneously encapsulated with PTX (1: 100) into PEG-
Hb NPs to fluorescently label the NPs. The cellular uptake
was evaluated by co-culturing the NPs with MCF-7 cells
and imaged using confocal laser microscope. As shown in
Figure 3(B), cou6 delivered by PEG-Hb NPs exhibited the
most efficient cytoplasmic translocation than free dye and
even Hb NPs. These results also explained the improved anti-
cancer cell activity indicated in Figure 3(A). The excellent sta-
bility of PEGylated NPs should contribute to the higher
cellular uptake and cytotoxicity (Figure 1(D)).
3.4. In vivo imaging of NPs
To evaluate whether PEGylated Hb NPs could improve drug
delivery to distant tumors via intravenous injection, we con-
ducted in vivo imaging and biodistribution study. IR775 was
co-encapsulated into NPs to evaluate biodistribution and
estimate tumor accumulation in mice bearing subcutaneous
H22 tumors. As shown in Figure 4(A), most of the fluores-
cence signal of IR775 concentrated in the liver within 3 h
after injection. After 1-h post-injection, a strong signal was
detected in the tumor area with PEG-Hb-IR775 NPs and the
tumor signal reached a peak after 24-h post-injection (Figure
4(A)). Quantification of fluorescent signals in the tumor area
Figure 2. Hydrophobic change of PEG-Hb at acid pH values. (A) Changes in Trp fluorescence in Hb solutions with pH values of 6.6, 6.0, and 4.0. (B) Exposure of
hydrophobic domains of Hb at pH 6.6, pH 6.0, and pH 4.0 as assessed by fluorescence emission spectra of ANS bound to PEG-Hb.
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Figure 3. Cytotoxicity and cellular uptake of PEG-Hb-PTX NPs in MCF-7 cells. (A) Cell viability of MCF-7 cells incubated with different concentrations of PTX for
24 h. (B) Confocal fluorescence images of MCF-7 cells incubated with free cou-6, Hb-PTX NPs, and PEG-Hb-PTX NPs for 2 h.
Figure 4. In vivo fluorescence imaging and biodistribution of free IR775, Hb-IR775, and PEG-Hb-IR775 NPs in H22 tumor-bearing mice. (A) NIR fluorescence imaging
after intravenous injection of PEG-Hb-IR775 NPs, Hb-IR775 NPs, and free IR775 (tumors indicated by black circle). The colors indicated that the fluorescence inten-
sity in the picture increased from blue to red. (B) Fluorescence intensity (F.I) of IR775 in the tumors of three groups. (C) Ex vivo fluorescence images of tumors and
major organs after administration at 72 h. (D) Semiquantitative assessment of biodistribution of IR775 after injection. p < 0.01.
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confirmed tumor accumulation of PEG-Hb-IR775 NPs
(Figure 4(B)). We also detected the distribution of IR775 in
tumor and major organs from the ex vivo images after 72-h
injection (Figure 4(C–D)). From both of the image and the
quantification of fluorescent signals, most of the IR775 accu-
mulated in livers. The accumulation of PEG-Hb-IR775 NPs in
tumor tissue was much higher than Hb-IR775 NPs and free
IR775. These results indicated that the PEGylated Hb NPs
could effectively accumulate in tumor tissues and ensured
successful anticancer therapy in vivo.
To further analyze the efficiency of PTX delivered by the
PEG-Hb NPs, we conducted a pharmacokinetic study. Plasma
PTX concentration–time profile was shown in Figure S4. And
a summary of the pharmacokinetic variables for PTX adminis-
tered as both PEG-Hb-PTX NPs and Taxol is presented in
Table S1. The results showed that the blood circulation half-
life of PEG-Hb-PTX NPs was significantly prolonged compared
to Taxol (1.06 vs. 0.39 h). The pharmacokinetic results showed
PEGylation strategy for hemoglobin is viable for delivering
PTX in vivo.
3.5. Anticancer activity of PEG-Hb-PTX NPs in vivo
The ability of the PEG-Hb-PTX NPs to inhibit the growth of
tumor was evaluated in H22-transplanted tumor-bearing
mice. When the tumor volume reached 100mm3, the treat-
ments were initiated. As shown in Figure 5(A), TaxolTM
showed great antitumor efficacy compared with that of the
PBS group, agreed with the clinical data. However, the PEG-
Hb-PTX NPs group exhibited better antitumor ability com-
pared with that in PBS group and even in TaxolTM group. In
the present study, the body weight changes were analyzed
as an indicator for treatment-induced toxicity. All the mouse
groups showed slightly increased body weights. The animals
treated with PEG-Hb-PTX NPs did not show significant
weight loss over the treatment period (Figure 5(B)).
4. Conclusion
In this study, we have successfully synthesized PEG-Hb and
prepared PTX-loaded NPs with PEG-Hb by acid-denatured
method. Due to the improving stability of PEG-Hb NPs, the
PEG-Hb-PTX NPs exhibited enhanced cellular uptake and
anticancer cell activity. PEGylated NPs could accumulate
more in tumor tissues and exhibited excellent anticancer
activity. The PEG-Hb NPs is a promising drug delivery system
to improve the therapeutic efficacy of anticancer drugs such
as PTX and offers great potential in translational applications
in anticancer treatments.
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